Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer (PRIMUS)
This study has been terminated.
(Due to enrollment challenges resulting from changing treatment patterns in the use of cetuximab, the study has been terminated. No patients remain on study.)
First Posted: March 4, 2011
Last Update Posted: July 13, 2017
Information provided by (Responsible Party):